MLTXNasdaqPharmaceutical PreparationsFiscal year ends December 31

MoonLake Immunotherapeutics

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$9.75+0.20 (+2.09%)

Close on Oct 19, 2026

Market cap: $720.67M
P/E (TTM): –
Dividend yield: –

MoonLake Immunotherapeutics income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research & Development	203	113	32	42	–
General & Administrative	42	30	22	23	4.57
Operating Expenses	245	143	54	65	–
Operating Income	-245	-143	-54	-65	-4.57
Interest Expense	7.25	0	0	–	–
Interest & Investment Income	–	–	–	–	0.03
Other Non-Operating Income	–	–	–	0.59	0.03
Pretax Income	-230	-121	-44	-64	–
Income Tax Expense	0.61	0.28	0.09	0.04	–
Net Income incl. Noncontrolling Interests	-230	-121	-44	-65	–
Minority Interest in Earnings	-3.00	-2.31	-8.07	-15	-4.54
Net Income	-227	-119	-36	-50	-4.54
EPS (Basic)(per share)	-3.53	-1.89	-0.73	-1.70	-0.31
EPS (Diluted)(per share)	-3.53	-1.89	-0.73	-1.70	-0.31
Shares Outstanding (Basic, Weighted)(shares)	64	63	49	29	12
Shares Outstanding (Diluted, Weighted)(shares)	64	63	49	29	360
EBITDA	-242	-142	-54	-65	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -60.5%

Financial strength

Current ratio: 12.56
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1052.8%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.68
Dividend yield: –